Cyclacel Pharmaceuticals (CYCC) Competitors $6.44 -0.33 (-4.87%) Closing price 09/11/2025Extended Trading$6.44 0.00 (0.00%) As of 09/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYCC vs. GANX, DTIL, PRLD, ICCC, GNTA, CUE, ACRV, ATNM, RLMD, and INMBShould you be buying Cyclacel Pharmaceuticals stock or one of its competitors? The main competitors of Cyclacel Pharmaceuticals include Gain Therapeutics (GANX), Precision BioSciences (DTIL), Prelude Therapeutics (PRLD), ImmuCell (ICCC), Genenta Science (GNTA), Cue Biopharma (CUE), Acrivon Therapeutics (ACRV), Actinium Pharmaceuticals (ATNM), Relmada Therapeutics (RLMD), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. Cyclacel Pharmaceuticals vs. Its Competitors Gain Therapeutics Precision BioSciences Prelude Therapeutics ImmuCell Genenta Science Cue Biopharma Acrivon Therapeutics Actinium Pharmaceuticals Relmada Therapeutics INmune Bio Gain Therapeutics (NASDAQ:GANX) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation. Do analysts recommend GANX or CYCC? Gain Therapeutics currently has a consensus price target of $8.00, indicating a potential upside of 346.93%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Cyclacel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the media favor GANX or CYCC? In the previous week, Gain Therapeutics had 3 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 3 mentions for Gain Therapeutics and 0 mentions for Cyclacel Pharmaceuticals. Gain Therapeutics' average media sentiment score of 1.20 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Gain Therapeutics Positive Cyclacel Pharmaceuticals Neutral Which has more risk & volatility, GANX or CYCC? Gain Therapeutics has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Is GANX or CYCC more profitable? Gain Therapeutics' return on equity of -289.10% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Gain TherapeuticsN/A -289.10% -155.11% Cyclacel Pharmaceuticals N/A -723.64%-145.51% Which has higher earnings & valuation, GANX or CYCC? Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGain Therapeutics$50K1,287.01-$20.41M-$0.63-2.84Cyclacel Pharmaceuticals$40K360.64-$11.21M-$839.58-0.01 Do insiders and institutionals believe in GANX or CYCC? 12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 7.2% of Gain Therapeutics shares are owned by insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryGain Therapeutics beats Cyclacel Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Cyclacel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYCC vs. The Competition Export to ExcelMetricCyclacel PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.43M$3.08B$5.64B$10.33BDividend YieldN/A2.44%5.79%4.65%P/E Ratio-0.0121.1975.7526.14Price / Sales360.64457.15557.16132.69Price / CashN/A44.6837.1160.83Price / Book-0.119.7412.416.36Net Income-$11.21M-$52.93M$3.29B$270.97M7 Day PerformanceN/A3.87%1.26%0.36%1 Month Performance-14.02%7.65%3.84%6.37%1 Year Performance-97.37%20.14%61.01%28.46% Cyclacel Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYCCCyclacel Pharmaceuticals0.1144 of 5 stars$6.44-4.9%N/A-97.4%$14.43M$40K-0.0114High Trading VolumeGANXGain Therapeutics2.9236 of 5 stars$1.74+10.1%$8.00+359.8%-2.8%$56.80M$50K-2.7620DTILPrecision BioSciences4.2558 of 5 stars$4.86+1.7%$47.00+867.1%-46.0%$56.34M$68.70M-0.55200Positive NewsPRLDPrelude Therapeutics3.428 of 5 stars$1.01+2.6%$4.00+296.0%-41.3%$55.74M$7M-0.62120News CoveragePositive NewsAnalyst ForecastAnalyst RevisionICCCImmuCell1.3735 of 5 stars$6.25+4.9%N/A+67.0%$53.91M$26.49M32.9070Positive NewsGap DownGNTAGenenta Science2.7969 of 5 stars$2.97+3.7%$25.00+742.9%-25.2%$52.31MN/A0.007Gap UpCUECue Biopharma2.3987 of 5 stars$0.70+4.7%N/A+45.3%$51.65M$9.29M-1.2660Positive NewsACRVAcrivon Therapeutics3.6452 of 5 stars$1.66+1.8%$15.00+803.6%-78.5%$51.27MN/A-0.7458Positive NewsATNMActinium Pharmaceuticals2.101 of 5 stars$1.63+2.5%$4.50+176.1%-11.7%$50.85MN/A-1.1730RLMDRelmada Therapeutics2.8902 of 5 stars$1.65+7.8%$1.00-39.4%-50.9%$50.78MN/A-0.7410Positive NewsINMBINmune Bio3.3769 of 5 stars$1.98+4.2%$18.40+829.3%-58.2%$50.51M$10K-0.8010Positive News Related Companies and Tools Related Companies Gain Therapeutics Competitors Precision BioSciences Competitors Prelude Therapeutics Competitors ImmuCell Competitors Genenta Science Competitors Cue Biopharma Competitors Acrivon Therapeutics Competitors Actinium Pharmaceuticals Competitors Relmada Therapeutics Competitors INmune Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYCC) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqOn September 30, 2025, at midnight ET... a groundbreaking emergency order goes into effect, issued directly by...Altimetry | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYCC Stock Alerts